In addition, recent studies indicate that some GLP1R agonists, such as liraglutide, semaglutide, and dulaglutide, exert cardiovascular and renal benefits, and are endorsed for use in patients with these complications
Preventative healthcare instead of sick care
Taking into consideration immense challenges still present in diagnostics and therapy of lipid disorders, changes in the approach to treatment, including innovative molecules, as well as the most recent results of numerous studies (lipidology and atherosclerosis research are currently the most rapidly developing specialty in medicine), Polish Lipid Association (PoLA), along with College of Family Physicians in Poland (CFPiP), Polish Cardiac Society (PCS), Polish Society of Diabetology (PSD), Polish Society of Laboratory Diagnostics (PSLD), and Polish Society of Hypertension (PSH), decided to prepare comprehensive guidelines concerning management of lipid disorders, with special attention paid to the practical aspect of these guidelines, as we would like to make them an actual tool for everyday work with patients suffering from lipid disorders
Retatrutide vs Classic Weight-Loss Medications Older medications like phentermine, orlistat, and naltrexone/bupropion cannot match retatrutides metabolic efficiency
Wegovy is the brand name for semaglutide , a GLP-1 receptor agonist
